Charts
To Immunity and BeyondEpisode from the podcastTo Immunity and Beyond
Next Episode
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

Released Friday, 13th June 2025
Good episode? Give it some love!
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

Friday, 13th June 2025
Good episode? Give it some love!
Rate Episode
List
About
InsightsPodchaser Pro
Reviews
Credits
Lists
Transcript
spinner
Rate
List
Get this podcast via API

From The Podcast

In a series produced by the Oxford Immunology Network, Professor Paul Klenerman talks with colleagues about their recent ground-breaking publications, exploring the original scientific goals, challenges they encountered along the way, and future ambitions in the field. This series will be of interest to anyone studying or working in immunology, medical sciences, biology or related fields. NB: To Immunity and Beyond is for educational purposes only and should not be considered professional medical advice.

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more
Do you host or manage this podcast?
Claim and edit this page to your liking.
,
Podchaser Logo

Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More